

17th ANNUAL AWACC 2025
Ms PETRA ZAMA-MTHEMBU
DD- KZN PDOH -HAST

30 October 2025
Elangeni Hotel

OUTLINE

What is Lenacapavir for PrEP?

How does lenacapavir work?

Dosing schedule

Flow chart

Summary

Conclusion



HIV PRE-EXPOSURE PROPHYLAXIS

LONG ACTING INJECTABLE LENACAPAVIR FOR HIV PREVENTION



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



What is Lenacapavir for PrEP?

Lenacapavir belongs to a class of ARVs called capsid inhibitors that reduce the ability of HIV to multiply by damaging the protein shell of the HIV cell during the viral life cycle. It is systemic and is absorbed throughout the body.

Lenacapavir has been shown in clinical trials to be highly effective in preventing HIV acquisition.

Lenacapavir, if administered every six months, reduces the risk of HIV acquisition by at least 96%..

How does lenacapavir work?


Lenacapavir is a first-in-class capsid inhibitor with a novel mechanism of action, targeting HIV-1 at multiple stages of its life cycle.

It interferes with three essential steps of HIV replication, namely:

- **Nuclear Transport:** It disrupts the transport of the viral capsid into the host cell nucleus, preventing the integration of viral DNA into the host genome.
- **Virus Assembly and Release:** Lenacapavir affects the assembly and release of new viral particles from infected cells, hindering the production of new virions.
- **Capsid Core Formation:** Lenacapavir interferes with the formation of the capsid core, leading to malformed capsids, which are crucial for protecting the viral RNA and enzymes necessary for replication.

How does lenacapavir work?

LENACAPAVIR TARGETS MULTIPLE STAGES OF VIRAL REPLICATION



health

Department:
Health
REPUBLIC OF SOUTH AFRICA



Lenacapavir for PrEP dosing schedule

Dosing schedule for lenacapavir initiation and continuation in adults and adolescents weighing ≥ 35 kg

Day 1:

927 mg by subcutaneous injection
(2 x 1.5 mL injections)



600 mg orally (2 x 300 mg tablets)

Day 2:


600 mg orally (2 x 300 mg tablets)

Dosage of lenacapavir: continuation

Every 6-months
(26 weeks) $\pm$ 2 weeks

927 mg by subcutaneous injection
(2 x 1.5 mL injections)

Initiating Lenacapavir for PrEP



In Summary

- HIV prevention gap remains wide — especially among women and adolescents.
- Oral PrEP works but is hard to sustain — new options are needed.
- Lenacapavir is highly effective — zero infections in PURPOSE 1, only two in PURPOSE 2.
- Safe and well tolerated — AEs mostly mild, ISRs manageable, strong safety in pregnancy and lactation.
- Twice-yearly dosing is transformative — simple, discreet, and empowering.
- Evidence already shaping guidelines — FDA-approved, WHO-recommended, and poised for global rollout.



Conclusions

- PURPOSE 1 sets a new paradigm for ethical and inclusive trial design to accelerate data availability to support new PrEP options for pregnant and lactating people
- Twice-yearly LEN was efficacious, safe, and well tolerated in pregnant and lactating people
- No dose adjustment is required in pregnancy or post-partum
- 95% of eligible participants chose to continue or initiate LEN in the open-label extension, including participants who became pregnant during the RBP
- LEN for PrEP use in pregnancy supported in the US FDA label¹ and 2025 WHO Guidelines²

Proactive inclusion of pregnant and lactating women in PURPOSE 1 supports early adoption of LEN for PrEP in pregnant and lactating people

FDA, Food and Drug Administration; LEN, lenacapavir; PK, pharmacokinetics; PrEP, pre-exposure prophylaxis; RBP, randomized blinded phase; WHO, World Health Organization.

1. Gilead Sciences. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/220020s000lbl.pdf (accessed July 15, 2025). 2. World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. July 14, 2025 (<https://www.who.int/publications/i/item/9789240111608>)

Thank you



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

